ConductScience.org, home

Paper48151

Letter: In-vitro restoration by levamisole of thymus-derived lymphocyte functions in Hodgkin's disease.

Verhaegen H and 5 others. Lancet, 1975. Cited by 36 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Letter: In-vitro restoration by levamisole of thymus-derived lymphocyte functions in Hodgkin's disease. Papers, record 48151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/48151

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Letter: In-vitro restoration by levamisole of thymus-derived lymphocyte functions in Hodgkin's disease.
PubMed
Journal
Lancet
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
1.91
iCite
Revised in PubMed
2019-06-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Verhaegen HH
2De Cock WW
3De Cree JJ
4Verbruggen FF
5Verhaegen-Declercq MM
6Brugmans JJ

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hodgkin DiseaseMajor topic
LevamisoleMajor topic
T-LymphocytesMajor topic
Azathioprine
Dose-Response Relationship, Drug
Drug Antagonism
Humans
Immune Adherence Reaction
In Vitro Techniques

Source PubMed

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
6,553,512Restoration by levamisole of immune responses suppressed in tumor-bearing mice.Cancer Immunol Immunother1983https://conductscience.org/library/papers/6553512PubMed
6,234,912Effect of levamisole and azathioprine on the human mixed lymphocyte reaction (MLR).Br J Clin Pharmacol1984https://conductscience.org/library/papers/6234912PubMed
1,098,727Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma.Br Med J1975https://conductscience.org/library/papers/1098727PubMed
908,176The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients.Clin Exp Immunol1977https://conductscience.org/library/papers/908176PubMed
321,165Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases.Clin Exp Immunol1977https://conductscience.org/library/papers/321165PubMed
312,252Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole.Immunology1978https://conductscience.org/library/papers/312252PubMed
75,542Whipple's disease in a female with impaired cell-mediated immunity unresponsive to co-trimoxazole and levamisole therapy.Postgrad Med J1978https://conductscience.org/library/papers/75542PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/48151

GET https://conductscience.org/api/papers/v1/48151/authors